CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to determine the influence of baseline HbA1c in the Assessment of…
DOI 10.1055/s-0034-1375120
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Bain, Z Skrivanek, A Tahbaz, V Pechtner, O Adetunji
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aim: To investigate the response to long- and short-acting glucagon-like peptide-1 receptor agonists based on baseline HbA1c levels. The AWARD-1 trial compared once weekly dulaglutide 1.5 mg and dulaglutide 0.75 mg to placebo and exenatide 10 µg bid in patients with T2DM on metformin and pioglitazone. Methods: The changes from baseline in HbA1c and percentages of patients reaching HbA1c targets (< 7.0%, ≤6.5%) with…
Zitieren
Zitierempfehlung
S Bain, Z Skrivanek, A Tahbaz, V Pechtner, O Adetunji (2014) Efficacy of long acting once weekly dulaglutide compared with short acting twice-daily (bid) exenatide in patients with Type 2 diabetes mellitus (T2DM): a post-hoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly AdministRation of LY2189265 in Diabetes-1 (AWARD-1) t…. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1375120
Mit CareLit weiterarbeiten